Gregory Miller joins Concert Pharmaceuticals
This article was originally published in Scrip
Concert Pharmaceuticals (US), a clinical-stage biotech company focused on applying its DCE Platform to create small-molecule drugs containing deuterium, has named Gregory Miller head of business and corporate development. He was most recently senior director of business development and corporate strategy at AMAG Pharmaceuticals. Before that, Mr Miller served in several analytical and leadership roles in the corporate development group at Genzyme.